Weekly cisplatin shows similar burden of acute treatment side effects as every 3-week schedule for patients with p16-negative head and neck cancer on NRG oncology trial
Shortened radiation schedule provides similar cancer control and patient-reported outcomes to standard radiation following surgery for high-risk prostate cancer in NRG Oncology trial
Addition of immunotherapy continues to show survival benefit in prolonged follow-up in NRG Oncology trial for primary advanced stage or recurrent endometrial cancer - EurekAlert!
